Addiction

MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication

Advancing toward Phase 2a clinical evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast...

UNIVERSITY OF MARYLAND, BALTIMORE AND AXIS RESEARCH & TECHNOLOGIES ANNOUNCE JOINT VENTURE TO BUILD NATION’S FIRST AI-POWERED SMART SURGICAL PERFORMANCE CENTER

New 36,000 sq. ft. facility will leverage OMNIMED SmartOR™ technology to integrate AI-driven data and performance analytics into surgical training, research,...

MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction

Closing adds $5 million in marketable securities, strengthens financial position, and complements MIRA's advancing programs including Ketamir-2 and MIRA-55 MIAMI,...

Branded Legacy, Inc. Announces Provisional Patent Filing by BioLegacy for Disruptive Air-Driven Intranasal Platform Targeting Multi-Billion-Dollar Global Therapeutics Market

Revolutionary platform aims to make life-saving overdose reversal therapies more affordable, accessible, and effective worldwideVANCOUVER, British Columbia, Sept. 30, 2025...

error: Content is protected !!